Buffett InvestorsNZX
Back
SML.NZ

Synlait Milk Just Sold Its North Island Assets for $307M - So Why Did Debt Still Jump 88%?

A Dairy Turnaround With More twists Than a Milkshake

Synlait Milk NZX stock has been on a rough ride. At around $0.43 NZD, the share price is roughly half its 52-week high of $0.835 and the company is burning through cash faster than a milk dryer in peak season. The Canterbury-based dairy processor just reported a thumping $80.6 million net loss for the first half of FY2026, even as revenue ticked up to $949 million. Yet shareholders did get one piece of genuinely good news in April: the completion of a $307 million sale of Synlait's North Island assets to Abbott Laboratories. So why did net debt still surge 88% to $472.1 million? And more importantly, is there any value left for investors at 43 cents?

Recent Performance: Stuck Near the Bottom

The Synlait Milk share price has been trapped in a tight range for months, oscillating between roughly $0.415 and $0.455 over the past 30 days. Volume is thin, and the market cap sits at approximately $260 million NZD - a fraction of where the company traded during its infant-formula boom years. There is no dividend, and with a trailing EPS of roughly -$0.19, the P/E ratio doesn't even exist. Analysts are cold on the stock. The consensus 12-month price target is just $0.45 NZD, with a range from $0.40 to $0.53. In broker-speak, that is essentially a "hold your nose and watch" rating.

What Went Wrong in the First Half?

HY26 was ugly. Three core issues collided at once:

  • •Manufacturing plan adjustments: Following FY25 production disruptions, Synlait had to rebuild customer inventories on the fly. The revised plan left the company with surplus milk during peak season, which was sold tactically at poor prices. That alone cost an estimated $33.2 million.
  • •Lower Ingredients returns: Catch-up production forced Synlait into commodity whole milk powder just as global WMP prices tanked late in 2025. Ingredients gross profit collapsed 89%.
  • •Deferred tax assets: A non-cash accounting hit compounded the headline loss.

The result was an underlying net loss of $27.3 million (and a reported loss of $80.6 million) on revenue of $949 million. Gross profit imploded from $87 million a year ago to just $3.1 million. Operating cash flow was a brutal negative $183.4 million.

Even the company's crown jewel - the Advanced Nutrition business, which supplies infant formula to global brands - saw gross profit crater 87% as manufacturing challenges and inventory rebuilds destroyed margins.

The Abbott Sale: A Lifeline, Not a Magic Wand

On 2 April 2026, Synlait settled the sale of its North Island assets - including the Pokeno manufacturing facility and Auckland blending and canning sites - to Abbott Laboratories for $307 million. Of that, roughly $200 million went straight to debt repayment, and the company halved its bank facilities to $200 million.

That sounds like a big win, and it is - sort of. The sale removes the complexity of running a multi-site operation and lets Synlait focus on its core Canterbury hub at Dunsandel. But the debt level is still enormous for a company with a $260 million market cap. Net debt of $472 million (up from roughly $251 million a year earlier) means the balance sheet remains highly leveraged. And with operating cash flow deeply negative, Synlait is still relying on asset sales and lender patience to stay afloat.

The Recovery Roadmap: Stabilise, Simplify, Scale

Management has laid out a three-phase recovery plan that sounds sensible on paper:

  • •Stabilise: Fix operational reliability at Dunsandel, rebuild customer trust, and tighten quality controls - especially for Chinese regulatory standards.
  • •Simplify: Cut costs, shrink the revenue team, close the Palmerston North office (saving ~$2 million per year), and focus on higher-margin products using existing assets.
  • •Scale: Eventually grow into new markets and channels once the core business is steady.

The challenge is that phase one is expensive and painful. Surplus milk is still being managed, customer inventories are still being rebuilt, and the company has withdrawn FY26 guidance entirely - never a confidence builder.

What to Watch

  • •Debt trajectory: The Abbott proceeds bought time, but net debt still climbed. Watch for further asset sales or equity raises if cash burn continues.
  • •Manufacturing stability: Dunsandel needs to run cleanly for several quarters before investors will trust the operational story.
  • •China demand: Advanced Nutrition is Synlait's highest-margin segment, and Chinese regulatory scrutiny is tightening. Any disruption here would be devastating.
  • •FY26 results: With no guidance, the full-year result is a complete unknown. Expect volatility when it lands in September 2026.
  • •Milk supply costs: The forecast average milk payment for FY26 is $9.90/kgMS - a high-cost input that leaves little room for error.

The Bottom Line

Synlait Milk is a classic high-risk turnaround story. The Abbott sale was necessary and removes a major distraction, while the recovery roadmap at least gives shareholders a narrative to cling to. But the numbers don't lie: gross profit has evaporated, debt has ballooned, and the company has no guidance, no dividend, and barely any analyst support. At $0.43, you are betting that management can stabilise Dunsandel, rebuild margins, and avoid another capital raise. If they pull it off, the upside could be meaningful from these depressed levels. If they don't, the next stop could be a deeply discounted equity raising or worse. This is a punt, not an investment - and it is only for investors with a high tolerance for risk and a very long horizon.

*Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice. Stock data may not be real-time. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.*